PLUS1
12.45
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Athenex Inc | ATNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.55 | 4.62% | 12.45 | 12.05 | 12.76 | 12.24 | 11.90 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 10.55 | 15.00 | 4.45 | 29.67% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,883 | 636,392 | $ 12.51 | $ 7,961,242 | 506,307 | 5.63 - 22.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:35:02 | 5 | $ 12.45 | USD |
Athenex Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.02B | 81.63M | 61.39M | $ 101.23M | $ -89.83M | -1.68 | -11.31 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 19.00 | 9.10% |
Athenex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/19/2020 | 09:05 | GlobeNewswire Inc. | Athenex Announces Participation in the 2020 RBC Capital.. |
| 5/14/2020 | 14:14 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 5/13/2020 | 16:22 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 5/07/2020 | 12:03 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 5/07/2020 | 07:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/07/2020 | 07:00 | GlobeNewswire Inc. | Athenex, Inc. Reports First Quarter Ended March 31, 2020.. |
| 4/29/2020 | 13:54 | GlobeNewswire Inc. | Athenex Announces Acceptance of Oral Paclitaxel Phase II.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATNX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.13 | 12.76 | 10.50 | 11.52 | 532,551 | 1.32 | 11.86% |
| 1 Month | 9.35 | 12.76 | 9.1225 | 11.01 | 484,269 | 3.10 | 33.16% |
| 3 Months | 8.89 | 12.76 | 5.63 | 8.74 | 628,735 | 3.56 | 40.04% |
| 6 Months | 16.13 | 22.00 | 5.63 | 11.96 | 743,242 | -3.68 | -22.81% |
| 1 Year | 14.60 | 22.00 | 5.63 | 13.40 | 787,395 | -2.15 | -14.73% |
| 3 Years | 12.00 | 22.00 | 5.63 | 14.15 | 464,090 | 0.45 | 3.75% |
| 5 Years | 12.00 | 22.00 | 5.63 | 14.15 | 464,090 | 0.45 | 3.75% |
Athenex Description
| Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company's operating segment includes the Oncology Innovation Platform; Global Supply Chain Platform and Commercial Platform. It generates maximum revenue from the Commercial Platform segment. Commercial Platform segment includes APD, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. Geographically, it derives a majority of revenue from the United States and also has a presence in Spain; Austria; India; China; the United Kingdom and Other foreign countries. |
